Patent EP0286224A2 successfully refreshed from Google Patents.
EP0286224A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Treatment of human viral infection by dsRNA combined with viral inhibitors
Assignee: HEM Pharmaceuticals Corp
•
Filing: 1988-03-02
•
Granted: —
•
Expires: 2008-03-02
Abstract
Abstract Synergistic combinations of dsRNAs and anti-viral agents in the treatment of viral diseases indicates dsRNA, especially mismatched dsRNA, plays a powerful and versatile role as a core drug in combination therapy for human viral pathogens, notably for ARC and AIDS.
Inventors
- 👤 William A. Carter
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-07 14:06
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; A61P; A61P31/00; A61P31/12; A61P31/14; A61P31/18; A61P43/00
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
33 words
Product containing dsRNA and an antiviral agent as a combined preparation for simultaneous, separate or sequential use in the treatment of a viral disease by inhibition of viral activity, viral expression or both.
Claim 2
Dependent Claim
33 words
Product containing dsRNA and an antiviral agent as a combined preparation for simultaneous, separate or sequential use in the treatment of a viral disease by inhibition of viral activity, viral expression or both.
Claim 3
Dependent Claim
16 words
The product of claim 1, which is a therapeutic composition comprising dsRNA and the antiviral agent.
Claim 4
Dependent Claim
27 words
The product of claim 1 or claim 2, wherein the antiviral agent is a cytokine, an inhibitor of reverse transcriptase, a lipophile or a glycoprotein processing inhibitor.
Claim 5
Dependent Claim
22 words
The product of claim 3, in which the antiviral agent is rIFN-α, r-IFN-β, rIRN- , azidothymidine, phosphoroformate, ribavirin, amphotericin B or castanospermine.
Claim 6
Dependent Claim
18 words
The product of claim 4, wherein the antiviral agent is 3ʹ-azido, 3ʹ-deoxythymidine or a pharmaceutically acceptable salt thereof.
Claim 7
Dependent Claim
16 words
The product of any one of claims 1 to 5, wherein the dsRNA is mismatched dsRNA.
Claim 8
Dependent Claim
18 words
The product of claim 6, wherein the dsRNA is of the general formula rI n (C₁₁₋₁₄U) n .
Claim 9
Dependent Claim
19 words
The product of claim 6, wherein the dsRNA is of the general formula rI n r(C₂₉, G) n .
Claim 10
Dependent Claim
18 words
The product of any one of claims 6 to 8, wherein the dsRNA contains regions of bond breakage.
Claim 11
Dependent Claim
20 words
The product of claim 1 or claim 2, wherein the dsRNA is Ampligen and the antiviral agent is 3ʹ-azido, 3ʹ-deoxythymidine.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.